Get notified when RNAZ files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Defj, Llc ("defj") (new) — Concentration of selling stockholders: a single entity, DEFJ, holds the majority of shares being registered for resale, which could lead to significant selling pressure.
- Each of Which Is Convertible Into 10,000 Shares of Common Stock (new) — High conversion ratio for Series A and B preferred stock implies substantial dilution for existing common stockholders.
Transcode Therapeutics registers resale of 15.96M shares by selling stockholders, led by DEFJ
Filed July 20, 2026 · ~1 min read
Key Changes
-
high
The prospectus covers resale of up to 15,955,543 shares of common stock by selling stockholders; the company receives no proceeds.
The Offering verify on EDGAR → -
high
DEFJ, LLC is the primary selling stockholder, holding the majority of shares registered for resale, creating potential selling pressure.
The Offering verify on EDGAR → -
high
Series A and B preferred stock convert at 10,000 common shares per preferred share, implying substantial dilution for existing holders.
The Offering verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade RNAZ commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify